HCMR Re-Imaging Study

Recruiting now

Conditions studied: Hypertrophic Cardiomyopathy (HCM)

In brief

This study aims to learn what might predict heart problems (like sudden death from a fast heart rhythm or heart failure) in people with a genetic condition called hypertrophic cardiomyopathy (HCM). HCM causes the heart muscle to become thick, which can make the heart stiff and harder to work properly. It can also affect the heart's electrical system. This study is looking to enroll patients that were previously part of a research project called "HCMR - Novel Predictors of Outcome in Hypertrophic Cardiomyopathy." The results of that study are still being reviewed, but they might show that people who had a substance called Gadolinium (MRI contrast or dye) collected in their heart muscle may have a higher risk for heart problems, including sudden cardiac death. This is called "late gadolinium enhancement" (LGE). This study is aiming to do follow-up imaging on those patients to better understand how LGE affects people with HCM.

Key facts

Study ID

NCT07054073

Run by

Christopher Kramer

People needed

314

Starts

2026-03-30

Expected to finish

2027-07-01

Last updated by the study team

2026-03-18

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients in the original HCMR cohort with:
• Obstructive HCM
• Males and females between 18 and 65 years of age
• BMI < 35 kg/m2
• LVOT-G at entry as follows:
• Resting gradient ≥50 mmHg OR Resting gradient ≥30 mmHg and <50 mmHg with post-Valsalva LVOT-G ≥50 mmHg
• NYHA Class II or III or
• Non-obstructive HCM
• Same criteria as above except resting LVOT-G is <30mmHg and post-Valsalva gradient <50mm Hg
• BMI <40kg/m2
• Elevated NT-proBNP > 300 pg/mL at the time of enrollment
• LVEF ≥55%

You may not qualify if…

• Paroxysmal atrial fibrillation or flutter documented prior to entry.
• Paroxysmal or permanent atrial fibrillation requiring rhythm restoring treatment (eg, direct-current cardioversion, ablation procedure, or antiarrhythmic therapy) ≤6 months prior to entry. (This exclusion does not apply if atrial fibrillation has been treated with anticoagulation and adequately rate-controlled for >6 months.)
• History of syncope or sustained ventricular tachyarrhythmia with exercise within 6 months prior to entry.
• Pregnancy due to potential risk of gadolinium to the fetus
• Patients with a pacemaker that are pacer-dependent as they cannot undergo MRI

Where it is running

• University of Virginia — Charlottesville, Virginia, United States (enrolling)
• Brigham & Women's Hospital — Boston, Massachusetts, United States
• Tufts Medical Center — Medford, Massachusetts, United States
• University of Michigan — Ann Arbor, Michigan, United States
• Cleveland Clinic — Cleveland, Ohio, United States
• University Hospitals Birmingham NHS Foundation Trust — Birmingham, United Kingdom
• Northwestern — Evanston, Illinois, United States
• London Chest Hospital — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.